Public Health England turns its drug production facility into a limited companyBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h3780 (Published 10 July 2015) Cite this as: BMJ 2015;351:h3780
- Nigel Hawkes
Public Health England has transferred its drug development and production department to a new standalone company, Porton Biopharma, which will remain state owned. Its managing director, Roger Hinton, said that the change would enable the company to shape its own future, pursue more opportunities, and respond more rapidly to changes in global …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial